Myriad Genetics Acquisition of Counsyl, Inc.

05/29/2018

Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.

Myriad Genetics Acquisition of Counsyl, Inc.

^DCounsyl

- Global leader in reproductive testing market
- Core products are Foresight[™] expanded carrier screening test and Prelude[™] non-invasive pre-natal screening test
- Calls on OBGYNs, reproductive endocrinologists, and maternal fetal medicine specialists
- Testing services provided from Counsyl's CLIA laboratory in South San Francisco, CA

Strategic Rationale

- Entry into high-growth reproductive testing market
- · Comprehensive women's health product offering
- Broad reimbursement coverage with potential for further expansion
- Potential for revenue synergies by tripling reproductive testing reach
- · Potential for cost synergies throughout the enterprise

Consideration For Counsyl Shareholders

- Acquiring Counsyl for \$375M consisting of cash and MYGN common stock
- · Funding deal using cash on hand and existing revolving credit facility
- Expected to close in 1Q19

Myriad Financial Considerations

- Trailing twelve month revenue of \$134M
- Will be neutral to adjusted EPS in FY19; >\$0.20 accretive in FY20
- Counsyl will be incorporated into FY19 financial guidance provided on 4Q18 earnings call
- Expect attractive ROIC profile creating significant shareholder value



Comprehensive women's health product offering



Broad reimbursement with potential for future expansion



Potential for revenue synergies by tripling reproductive testing reach



Counsyl's Portfolio of Women's Health Products

Allows Entry Into High-Growth Reproductive Testing Market

Counsyl Foresight





Expanded Carrier Screening

Non-Invasive Prenatal Screening

Hereditary Cancer Testing




Clinical decision support for identifying inheritable disorders

Clinical decision support for chromosome conditions Clinical decision support for up to nine cancers

Snapshot of Counsyl


Rapidly Growing Diagnostic Business in Women's Health Market



Expanded Carrier Screening Market Opportunity Multiple Opportunities for Growth

Large, Expanding Market For ECS


≈4.2 Million Pregnant Women



NIPS Market Expansion


Advancing Towards Standard of Care for All Women

≈4.2M Pregnancies in the U.S. Annually



Rapid Growth Expected in Reproductive Testing Market 60% Increase in U.S. Test Volume Over Next Five Years

U.S. Reproductive Testing Market



Reproductive health market grows at low double-digit rate to **3.5M tests** by FY23



Comprehensive women's health product offering



Broad reimbursement with potential for future expansion



Potential for revenue synergies by tripling reproductive testing reach



Strong Strategic Fit Within ⁴⁶ Strategy Announcing Formation of Women's Health Business Unit


	Risk?	Diagnosis?	Prognosis?	Therapy?
myriad. women's health	MYRIAD Hereditary Cancer riskScore	면 Counsyl Foresight 면 Counsyl Prelude		genesight
myriad. ONCOLOGY	MYRIAD Risk® Hereditary Cancer		Endo Predict [®]	myriad Choice
myriad. urology	MYRIAD Risk® Hereditary Cancer		🔁 Prolaris [.]	
myriad. DERMATOLOGY		MYRIAD Path		
myriad. NEUROSCIENCE		MYRIAD Path *		genesight
myriad. AUTOIMMUNE			Vectra DA	

* Future potential product

Comprehensive Women's Health Product Offering


Best-in-Class Suite of Products Addressing >\$5.0B U.S. Market

myriad. WOMEN'S HEALTH



Market Leading Expanded Carrier Screening Product High-Growth Opportunity in \$2.0B U.S. Market

已 Counsyl Foresight



Expanded Carrier Screening (ECS):

Testing for over 175 recessive genetic disorders in prospective parents to assess risk in future children

- Counsyl is the market leader with ≈20% market share
- Traditionally patients have been screened for cystic fibrosis, spinal muscular atrophy and fragile X but rapid growth is occurring in ECS
- ACOG updated guidelines in CY17 supporting ECS
- Highest detection rate of any test currently on the market

Rapidly Gaining Market Share in NIPS Market High-Growth Opportunity in \$2.0B U.S. Market

已 Counsyl Prelude

Non-Invasive Prenatal Screening:

Testing for trisomies, sex chromosome disorders and microdeletions in a developing fetus using maternal blood



- Prelude growth has significantly exceeded the market growth rate and currently has 8% market share
- Replaces serum-based markers and nuchal translucency with more accurate screening test
- ACOG professional guidelines could expand to provide greater access for average risk women
- Lowest cancellation rate of any test on the market



Comprehensive women's health product offering



Broad reimbursement with potential for future expansion



Potential for revenue synergies by tripling reproductive testing reach



Guideline Support For ECS and NIPS Increasing

Driving Expanded Reimbursement Coverage

Society for Motional Company Society for Motional Company	January 2015	Any patient may choose cell-free DNA (cfDNA) analysis as a screening strategy for common aneuploidies regardless of her risk status.
AVERCAN SOCIETY HUMAN GENETICS	March 2015	Comparably good results can be achieved in general obstetrical populations, making NIPT an alternative to current first-trimester screening protocols.
ispd International Society for Prenatal Diagnosis	April 2015	cfDNA screening as a primary test offered to all pregnant women currently is considered an appropriate protocol option.
Society for Material Granding	March 2016	All women should be offered the option of aneuploidy screening or diagnostic testing for fetal genetic disorder, regardless of maternal age.
Society for Material Society of Material - Fetol Medicine	May 2016	The sensitivity and specificity in the general obstetric population are similar to the levels previously published for the high-risk population.
	July 2016	Inform all pregnant women that NIPS is the most sensitive screening option for traditionally screened aneuploidies (i.e. Patau, Edwards, and Down syndromes).
National Boolety of Genetic S Counselors	October 2016	Supports prenatal cfDNA screening, also known as NIPT or NIPS, as an option for pregnant patients.
	April 2017	For scenarios in which different testing options are acceptable alternatives, obstetrician- gynecologists and other health care providers should determine which tests will be offered as the standard in their practices.

Potential Reimbursement Catalysts

Several Opportunities to Expand Coverage With Prelude and Foresight

ि Counsyl	ि Counsyl
Foresight	Prelude
 Further guideline support for expanded carrier screening New ECS code at higher contracted ASP 	 Further guideline support for average risk NIPS testing Average risk NIPS coverage expansion Medicaid coverage expansion Microdeletion coverage



Comprehensive women's health product offering

\$

Broad reimbursement with potential for future expansion

Potential for revenue synergies by tripling reproductive testing reach





- Largest genetics sales force in women's health
- 3x physician reach for Counsyl's tests
- Potential cross-selling opportunities in hereditary cancer
- 2x the size of the next largest competitor sales force
- 5% increase in market share = \$50M in revenue and \$25M in EBITDA



Comprehensive women's health product offering



Broad reimbursement with potential for future expansion



Potential for revenue synergies by tripling reproductive testing reach




Potential for Cost Synergies Through the Enterprise Experienced Integration Team Managing Project

- Same integration leadership with similar approach to the Assurex acquisition
- Leverage enterprise-wide functions such as R&D and Payer Markets
- Standardize informatics and IT platforms
- Leverage supplier purchasing power
- Combine commercial organizations
- Will look to combine the best functions and processes from both companies



Workflow Solution for the Busy OB/GYN

Innovative Process, Price and Information Transparency for Physicians and Patients



Myriad Genetics Acquisition of Counsyl, Inc.

^但Counsyl

- Global leader in reproductive testing market
- Core products are Foresight[™] expanded carrier screening test and Prelude[™] non-invasive pre-natal screening test
- Calls on OBGYNs, reproductive endocrinologists, and maternal fetal medicine specialists
- Testing services provided from Counsyl's CLIA laboratory in South San Francisco, CA

Strategic Rationale

- Entry into high-growth reproductive testing market
- · Comprehensive women's health product offering
- Broad reimbursement coverage with potential for further expansion
- Potential for revenue synergies by tripling reproductive testing reach
- · Potential for cost synergies throughout the enterprise

Consideration For Counsyl Shareholders

- Acquiring Counsyl for \$375M consisting of cash and MYGN common stock
- · Funding deal using cash on hand and existing revolving credit facility
- Expected to close in 1Q19

Myriad Financial Considerations

- Trailing twelve month revenue of \$134M
- Will be neutral to adjusted EPS in FY19; >\$0.20 accretive in FY20
- Counsyl will be incorporated into FY19 financial guidance provided on 4Q18 earnings call
- Expect attractive ROIC profile creating significant shareholder value